Strategic Acquisition Actylis recently acquired Pharm Rxchem, enhancing its portfolio of specialty ingredients for the vitamin, mineral, and supplement markets, which presents growth opportunities in the nutraceutical and pharmaceutical supply chains.
Innovative Expansion The company has expanded its manufacturing facilities in Eugene, Oregon, and Montreal, Canada, with new ISO Class 7 cleanroom space and cgmp Water for Injection systems, indicating capacity for high-volume biopharmaceutical production.
Strong Industry Presence Actylis operates in the life sciences and specialty chemicals sectors with a revenue range of $250 million to $500 million, demonstrating robust market engagement and potential for upselling advanced raw material solutions.
Leadership & Growth The appointment of Scott Thomson as CEO signals a strategic focus on growth and innovation, creating opportunities for sales teams to align with a forward-moving leadership vision in critical ingredients procurement.
Technology Utilization Utilizing advanced tech such as Microsoft Azure, Python, and GMP manufacturing protocols, Actylis offers opportunities to introduce specialized tech-enabled solutions for supply chain optimization and quality assurance in critical raw materials.